Stay updated with breaking news from Binding Affinity. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In their recent study posted to the preprint server bioRxiv*, the researchers from China have shown that tuftsin, a natural phagocytosis-stimulating peptide, can effectively impair the binding of SARS-CoV-2 spike S1 subunit to ACE2 receptor in a dose-dependent manner and therefore can be considered a potential drug against SARS-CoV-2 infection.
A new study describes the potential of engineered neutralizing antibodies that have a high affinity for the binding epitopes.
The scientists in this study used pooled convalescent serum to examine the serologic response in a population at risk of infection.
An interesting preprint research paper describes structural changes resulting from the multiple mutations found in the recent Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is the causative agent behind the coronavirus disease 2019 (COVID-19) pandemic. In addition, the research describes the consequent effects of these changes on Omicron’s infectivity and immune evasion capabilities.
Researchers combine SARS-CoV-2 spike vaccination with single-cell B-cell receptor sequencing technology to discover neutralizing antibody candidates.